IMMX · Immix Biopharma
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $10.74
Note written ·
Price against the kill line
27.0% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $10.74, on record since 11 November 2026. The shares are down 30.9% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $10.74, over both the 50-day and 200-day moving averages and just under the $11.00 September offering price, would show the shares leading again. A 14 December 2026 ASH update with the complete-response rate at or above 89% and no relapses would point the same way.
Research onlyNot in the portfolio.
Catalyst
The business · as of
Immix Biopharma is a clinical-stage company developing NXC-201, an investigational CAR-T cell therapy for relapsed or refractory light-chain (AL) amyloidosis. It has no product revenue; it funds development with equity sales. Net loss was $14 million in the quarter to 30 September 2026.
What is changing, and what follows · as of
- What is changing now
- On 12 November 2026 Immix filed its third-quarter 10-Q: net loss of $14 million and cash and short-term investments of $336 million at 30 September 2026, with no debt reported.
- What follows for the company
- Cash rose from $232.1 million at 30 June 2026 after the September offering. Quarterly net loss was $14 million against $11.6 million in the second quarter; the diluted share count is up 132.1% from a year earlier.
- What follows for its customers, suppliers and competitors
- Immix has no product revenue and no named customers. The next outside reading is the 14 December 2026 ASH oral presentation, where hematology specialists review the 45-patient data.
What the price assumes · as of
At the 13 November 2026 close (filed inputs to 12 November 2026) the shares trade at 2.0 times book value, with a free-cash-flow yield of −6.9% and an enterprise value of $321 million with no debt reported. Revenue is not reported, so the price rests on NXC-201 data holding through the planned mid-2027 BLA while $336 million of net cash funds a $45 million annual cash burn.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 12 November 2026; valuation at the 13 November 2026 close
- Free cash flow, four quarters ($M)
- −45.2
- Net cash, cash less debt ($M)
- 336
- Free-cash-flow yield (%)
- −6.9
All filed numbers
What Immix Biopharma reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | −13.9 |
| Net income ($M) four quarters: −46.3 | −13.9 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +132.1 |
| Operating cash flow ($M) | −44.9 |
| Capital spending ($M) | 0.3 |
| Free cash flow ($M) | −45.2 |
| Cash and short-term investments ($M) | 336 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 336 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 335 |
| Market value ($M) | 657 |
| Enterprise value, market value plus net debt ($M) no debt reported | 321 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 2.0 |
| Free-cash-flow yield (%) | −6.9 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 12.8% of shares outstanding sold short, 7.5 days of average trading to cover, +3.1% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $10K | $0 |
The thesis
Immix Biopharma's CAR-T therapy NXC-201 has strong interim data, but the shares are more likely to lag the S&P 500 than lead it while they trade below both 2026 offering prices. The oral presentation at the American Society of Hematology (ASH) meeting on 14 December 2026 settles whether the 89% complete-response rate holds up under a full public review.
The shares closed at $7.84 on 13 November 2026. That is under the $8.94 price of the 21 May 2026 offering and the $11.00 price of the 29 September 2026 offering. It is also under the 50-day average of $9.82 and the 200-day average of $9.62 (adjusted daily closes), and the shares are down 30.9% over three months. The 52-week intraday high of $15.10 came on 25 August 2026; the last close is 48.1% below it.
On 29 September 2026 the company reported an 89% complete-response rate across 45 patients with relapsed or refractory light-chain (AL) amyloidosis, and said it plans a biologics license application (BLA) submission in mid-2027. NXC-201 is an investigational chimeric antigen receptor T-cell (CAR-T) therapy.
The third-quarter 10-Q, filed 12 November 2026, shows cash and short-term investments of $336 million at 30 September 2026, no debt reported, a quarterly net loss of $14 million and earnings per share of $(0.19), in line with expectations. The shares closed at $8.66 on 11 November 2026, $8.07 on 12 November 2026 and $7.84 on 13 November 2026, so the report did not draw buyers.
At the 13 November 2026 close, the market value was $657 million against $336 million of net cash. The price reflects the interim data and two large financings; a close below both offering prices shows the market has not paid up for the data since the September raise.
Bullish and bearish views on Immix Biopharma, Inc.
The bull case on Immix Biopharma, Inc. (IMMX), in brief: expanded cohort kept a high response rate. The bear case: shares trade below both offering prices.
Bull case
- Expanded cohort kept a high response rate. Immix reported on 29 September 2026 an 89% complete-response rate in all 45 NEXICART-2 patients, assessed by an independent review committee. At ASH 2025 the same trial showed complete responses in 15 of 20 patients (75%), so the rate rose in the larger group.
- A full data review is scheduled. Immix announced on 4 November 2026 that the 45-patient results were selected for an oral presentation (abstract 826) on 14 December 2026 at 11:15 AM Central Time. The presentation will carry safety and efficacy detail beyond the September press release.
- Safety was clean at the interim. Immix reported no observed neurotoxicity or enterocolitis, and no relapses among patients who reached complete response or minimal residual disease negativity (company release, 29 September 2026).
- Regulatory designations are in place. NXC-201 holds FDA Regenerative Medicine Advanced Therapy and orphan drug designations, and received FDA Breakthrough Therapy designation for relapsed or refractory AL amyloidosis in January 2026 (September prospectus supplement, Form 424B5).
- Funding is large relative to spending. The third-quarter 10-Q reported $336 million of cash and short-term investments at 30 September 2026 and free cash flow of −$45 million over the four quarters to that date, so the cash covers the planned path to the mid-2027 BLA at the current spending rate.
- Analysts were positive on the September data. Needham maintained a Buy and raised its price target to $30 on 29 September 2026. Morgan Stanley kept Overweight with a $19 target on 11 August 2026.
Bear case
- Shares trade below both offering prices. The 29 September 2026 offering priced 11,363,637 shares at $11.00, and the 21 May 2026 offering priced 16,778,524 shares at $8.94. The close of $7.84 on 13 November 2026 is under both.
- Two raises in five months. Each sale put new supply into the market soon after positive news. The diluted share count was up 132.1% from a year earlier in the quarter to 30 September 2026 (10-Q filed 12 November 2026). No third raise is announced.
- Shares sit under both moving averages. The 13 November 2026 close of $7.84 is below the 50-day average of $9.82 and the 200-day average of $9.62, and 48.1% below the 52-week intraday high of $15.10 set on 25 August 2026.
- Durability is untested. The 89% rate is interim, from 45 patients, and the final readout is planned for mid-2027. A company with one lead clinical program has no other asset to offset a setback.
- News has not lifted the shares. After the 4 November 2026 conference announcement the shares closed at $7.97, then $7.20 on 5 November 2026. After the 12 November 2026 quarterly filing they closed lower on both 12 November 2026 and 13 November 2026.
Price setup
The shares closed at $7.84 on 13 November 2026, down from $8.66 on 11 November 2026 and above the $7.20 close of 5 November 2026. The $8.94 May offering price sits above that close, and the $11.00 September offering price is further above it.
The 200-day average of $9.62 and the 50-day average of $9.82 are the next overhead reference points. The three-month reference close was $11.34 on 17 August 2026. The 52-week closing low was $3.61 on 13 November 2025, so the shares remain well above their level of a year ago despite the three-month decline.
Across US stocks trading at least $5 million a day, the spread of 63-session returns (standard deviation) was 27% in 2026, so a wide range of outcomes in three months is normal for a single name.
SEC filings through 13 November 2026 list only the 8-K and 10-Q of 12 November 2026, and no Form 4 insider transactions.
Catalysts ahead
- 14 December 2026: ASH oral presentation of NEXICART-2 interim results, abstract 826, 11:15 AM Central Time. First detailed public review of the 45-patient safety and response data since the September release; it shows whether the 89% complete-response rate holds.
- ~30 June 2027 (est.): Final NEXICART-2 readout and planned BLA submission. The company's stated mid-2027 target; it decides whether the response rate holds with longer follow-up.
What would change the view
A daily close above $10.74, over both the 50-day and 200-day moving averages and just under the $11.00 September offering price, would show the shares leading again. A 14 December 2026 ASH update with the complete-response rate at or above 89% and no relapses would point the same way.
What it trades with
IMMX trades on its own clinical and financing news rather than with a peer group. Other cell-therapy and oncology developers respond to FDA policy and to biotech funding conditions, but none of them was the subject of company news that moved IMMX in the last 30 days. The shares' main sensitivity is to Immix's own data releases, the 14 December 2026 ASH presentation and any further equity issuance.
The evidence, claim by claim (8)
- Immix reported an 89% complete-response rate across 45 NEXICART-2 patients, no observed neurotoxicity or enterocolitis, and a planned BLA submission in mid-2027. Immix Biopharma release, 29 September 2026 (via press coverage) · as of
- NEXICART-2 interim results (45 patients) were selected for an oral presentation at ASH 2026: abstract 826, 14 December 2026 at 11:15 AM Central Time. Immix Biopharma release, 4 November 2026 · as of
- Cash and short-term investments were $336 million at 30 September 2026, with no debt reported; net loss was $14 million in the quarter and $46 million over four quarters. Third-quarter 2026 Form 10-Q, filed 12 November 2026 · as of
- Free cash flow was −$45 million over the four quarters to 30 September 2026; the diluted share count rose 132.1% from a year earlier. Third-quarter 2026 Form 10-Q, filed 12 November 2026 · as of
- Third-quarter earnings per share was $(0.19), in line with expectations. Company news, 12 November 2026 · as of
- Immix priced an 11,363,637-share offering at $11.00 per share. Immix Biopharma announcement, 29 September 2026 · as of
- Underwriting agreement covered 16,778,524 shares at $8.94 per share. Immix Form 8-K, 21 May 2026 · as of
- Cash, equivalents and short-term investments were $232.1 million at 30 June 2026; second-quarter net loss was $11.6 million. Second-quarter 2026 Form 10-Q, filed 7 August 2026 · as of
Sources
Related · shared themes
ORKA
Oruka Therapeutics
Oruka Therapeutics is modestly more likely to beat the S&P 500 over three months: its psoriasis antibody ORKA-001 cleared skin completely…
SMMT
Summit Therapeutics
Summit Therapeutics' case rests on FDA approval of ivonescimab in EGFR-mutant lung cancer by the 14 November 2026 goal date. The agency's…
XNCR
Xencor
Xencor's shares hold a modest edge over the S&P 500 on XmAb819's 45.5% confirmed response rate in advanced kidney cancer and cash funding…
ZLAB
Zai Lab
Zai Lab's shares are modestly more likely to beat the S&P 500 over three months on zoci, its DLL3 cancer drug with an 81.8% first-line…
See also · stocks to watch